Miravirsen (SPC-3649) is a potent miR-122 inhibitor and inhibits the biogenesis of miR-122. Miravirsen is a 15-nucleotide locked nucleic acid-modified phosphorothioate antisense oligonucleotide. Miravirsen inhibits HCV replication. Miravirsen can be used in research of HCV infection
In Vitro
Miravirsen is thought to work mainly by hybridizing to mature miR-122 and blocking its interaction with HCV RNA, its target sequence is also present in pri- and pre-miR-122. Miravirsen binds to the stem-loop structure of pri- and pre-miR-122 with nanomolar affinity, and inhibits both Dicer- and Drosha-mediated processing of miR-122 precursors. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Miravirsen (SPC-3649; 2.5-25 mg/kg; i.v.; daily, for 3 d) inhibits miR-122 activity in mice. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: NMRI female mice (27 g)Dosage: 2.5, 6.25, 12.5, and 25 mg/kg Administration: Intravenous injection; daily, for 3 days Result: Inhibited miR-122 activity in a dose-dependent manner.
Form:Solid
IC50& Target:miR-122
仕様
仕様と純度
≥98%
生化学的・生理学的メカニズム
Miravirsen (SPC-3649) is a potent miR-122 inhibitor and inhibits the biogenesis of miR-122. Miravirsen is a 15-nucleotide locked nucleic acid-modified phosphorothioate antisense oligonucleotide. Miravirsen inhibits HCV replication. Miravirsen can be used
Products are supplied to verified businesses, institutions, and qualified professionals for research and development use only. Not for use in humans, animals, diagnosis, or therapy.